Payment 2 PLATBY. In consideration for the proper performance of the Study by Institution in compliance with the terms and conditions of this Agreement, payments shall be made in accordance with the provisions set forth in Attachment A, with the last payment being made after the Site completes all its obligations hereunder, and Quintiles has received all properly completed CRFs and, if Quintiles requests, all other Confidential Information (as defined below). V souvislosti s řádným plněním Studie Poskytovatelem, a to v souladu s podmínkami a ustanoveními této Smlouvy, budou poskytovány platby dle podmínek a ustanovení definovaných v Příloze A, přičemž poslední platba bude uskutečněna poté, co Místo provádění klinického hodnocení splní a dokončí veškeré závazky, jež mu vyplývají z této Smlouvy, a Quintiles obdrží veškeré řádně vyplněné CRF a, bude-li tak Quintiles vyžadovat, veškeré další Důvěrné informace (ve smyslu níže uvedené definice).
Payment 2 PLATBY. In consideration for the proper performance of the Study by Institution in compliance with the terms and conditions V souvislosti s řádným plněním studie zdravotnickým zařízením, a to v souladu s podmínkami a ustanoveními této of this Agreement, payments shall be made in accordance with the provisions set forth in Attachment A, with the last payment being made after the Site completes all its obligations hereunder, and Quintiles has received all properly completed CRFs and, if Quintiles requests, all other Confidential Information (as defined below). All final invoices must be provided to Quintiles within sixty (60) days of termination or completion of the Study at Site in order to be processed for payment. In accordance with transparency laws governing pharmaceutical manufacturers’ interactions with healthcare professionals, Sponsor may be required to publicly disclose money and other items of value (e.g., food, hotel accommodations, travel, etc.) provided to Institution and/ or Investigator and Study Staff in connection with this Agreement. The extent of Sponsor’s required disclosure depends upon the applicable law, industry codes and its reporting requirements. The estimated value of financial payment under this Agreement shall be approximately CZK 113 136.
Payment 2 PLATBY. In consideration for the proper performance of the Study by Site in compliance with the terms and conditions of this Agreement, payments shall be made in accordance with the provisions set forth in Attachment A, with the last payment being made after the Site V souvislosti s řádným plněním Studie Místem provádění klinického hodnocení, a to v souladu s podmínkami a ustanoveními této Smlouvy, budou poskytovány platby dle podmínek a ustanovení definovaných v Příloze A, přičemž poslední platba bude uskutečněna poté, co Místo provádění klinického hodnocení splní a completes all its obligations hereunder, and XXXXX has received all properly completed CRFs and, if IQVIA requests, all other Confidential Information (as defined below). All final invoices must be provided to IQVIA within sixty (60) days of termination or completion of the Study at Site in order to be processed for payment. In accordance with transparency laws governing pharmaceutical manufacturers’ interactions with healthcare professionals, Sponsor (and its Affiliates) may be required to publicly disclose money and other items of value (e.g., food, hotel accommodations, travel, etc.) provided to Institution and/ or Investigator and Study Staff in connection with this Agreement, and Institution hereby acknowledges and consents to Sponsor and/or any of its Affiliates publically disclosing any and all such amounts and/or other items of value paid hereunder including related information about the Institution and Investigator (such as – when applicable - the Institution/ Investigator’s full name, place of work, private address, authorization number etc.) as may be required by any federal and/or state law, industry code/ guidelines, and/or Ferring policy. The extent of Sponsor’s required disclosure depends upon the applicable law, industry codes and its reporting requirements. The Institution also acknowledges and consents to that Sponsor is entitled to pass on/share the above mentioned information with/to its Affiliates in order to provide the relevant Affiliate(s) with the information needed by the Affiliate to comply with any healthcare professionals-reporting/ compliance regulation contained in any (to the Affiliate applicable) federal and/or state law, industry code/ guidelines, and/or Ferring policy. Investigator will provide Sponsor with a list of all the healthcare professionals who will be involved in performing the Study (containing their full names, private addresses, personal registration num...
Payment 2 PLATBY. In consideration for the proper performance of the Study by Site in compliance with the terms and conditions of this Agreement, payments shall be made in accordance with the provisions set forth in Attachment A, with the last payment being made after the Site V souvislosti s řádným plněním Klinického hodnocení Centrem klinického hodnocení, a to v souladu s podmínkami a ustanoveními této Smlouvy, budou poskytovány platby dle podmínek a ustanovení definovaných v Příloze A, přičemž poslední platba bude completes all its obligations hereunder, and IQVIA has received all properly completed CRFs and, if IQVIA requests, all other Confidential Information (as defined below). The estimated value of financial payment under this Agreement shall be approximately CZK 2 838 190, -. Iqvia Clinical Trial Payments will receive Site invoices and process payments unless otherwise agreed. Any queries regarding Site invoices or payments should be directed to Iqvia Clinical Trial Payments at the contact details outlined in Attachment A. uskutečněna poté, co Centrum klinického hodnocení splní a dokončí veškeré závazky, jež mu vyplývají z této Smlouvy, a IQVIA obdrží veškeré řádně vyplněné CRF a, bude- li tak IQVIA vyžadovat, veškeré další Důvěrné informace (ve smyslu níže uvedené definice). Předpokládaná hodnota finančního plnění dle této Smlouvy činí přibližně 2 838 190 Kč. Nebude-li ujednáno jinak, faktury od Centra klinického hodnocení obdrží a platby bude zpracovávat společnost Iqvia Clinical Trial Payments. Veškeré dotazy ohledně faktur CentraCentra klinického hodnocení nebo plateb mají být adresovány společnosti Iqvia Clinical Trial Payments, jejíž kontaktní údaje jsou uvedeny v Příloze A.
Payment 2 PLATBY
